Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II.
Timothy M E DavisJane KauhanenWendy A DavisPublished in: Internal medicine journal (2018)
Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5-yearly doses. In 1465 representative community-based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self-reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub-optimal coverage.